Novel Topical JAK Inhibitor for Atopic Dermatitis Treatment
Key Findings
Topical JAK inhibitor achieved 58% IGA 0/1 response at week 8. Rapid itch relief within 24 hours in majority of patients.
Summary
Topical JAK inhibitor achieved 58% IGA 0/1 response at week 8. Rapid itch relief within 24 hours in majority of patients.
Study Design
Randomized, vehicle-controlled study in 600 patients aged 3-65 years with mild-to-moderate atopic dermatitis.
Methods
Twice-daily application for 8 weeks. Co-primary endpoints were IGA success and percentage change in EASI score.
Results
IGA 0/1: 58% vs 26% vehicle (p<0.001). Mean EASI reduction 68% vs 41%. Peak pruritus NRS improved -3.2 vs -1.1.
Conclusions
Topical JAK inhibitor offers effective, rapid treatment for atopic dermatitis across age groups with good tolerability.
Full Abstract
This study examined novel topical jak inhibitor for atopic dermatitis treatment in a comprehensive clinical investigation.